These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33394193)

  • 1. Acute peritoneal dialysis, complications and outcomes in 389 children with STEC-HUS: a multicenter experience.
    Coccia PA; Ramírez FB; Suárez ADC; Alconcher LF; Balestracci A; García Chervo LA; Principi I; Vázquez A; Ratto VM; Planells MC; Montero J; Saurit M; Gutiérrez MGPY; Puga MC; Isern EM; Bettendorff MC; Boscardin MV; Bazán M; Polischuk MA; De Sarrasqueta A; Aralde A; Ripeau DB; Leroy DC; Quijada NE; Escalante RS; Giordano MI; Sánchez C; Selva VS; Caminiti A; Ojeda JM; Bonany P; Morales SE; Allende D; Arias MA; Exeni AM; Geuna JD; Arrúa L
    Pediatr Nephrol; 2021 Jun; 36(6):1597-1606. PubMed ID: 33394193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage.
    Luna M; Kamariski M; Principi I; Bocanegra V; Vallés PG
    Pediatr Nephrol; 2021 Jun; 36(6):1499-1509. PubMed ID: 33205220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. coli Infection: a multinational embedded cluster crossover randomized trial (the HIKO STEC trial).
    Freedman SB; Schnadower D; Estes M; Casper TC; Goldstein SL; Grisaru S; Pavia AT; Wilfond BS; Metheney M; Kimball K; Tarr PI;
    Trials; 2023 May; 24(1):359. PubMed ID: 37245030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).
    Khalid M; Andreoli S
    Pediatr Nephrol; 2019 Dec; 34(12):2495-2507. PubMed ID: 30382336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diarrhoea-associated haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infections in New Zealand children: Clinical features and short-term complications from a 23-year cohort study.
    Wong W; Prestidge C; Dickens A; Ronaldson J
    J Paediatr Child Health; 2023 Mar; 59(3):493-498. PubMed ID: 36655863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and Treatment for Shiga Toxin-Producing
    Liu Y; Thaker H; Wang C; Xu Z; Dong M
    Toxins (Basel); 2022 Dec; 15(1):. PubMed ID: 36668830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome 10 years after Shiga toxin-producing E. coli (STEC)-associated hemolytic uremic syndrome: importance of long-term follow-up.
    Rosales A; Kuppelwieser S; Giner T; Hofer J; Riedl Khursigara M; Orth-Höller D; Borena W; Cortina G; Jungraithmayr T; Würzner R;
    Pediatr Nephrol; 2024 Aug; 39(8):2459-2465. PubMed ID: 38589699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008.
    Jenssen GR; Vold L; Hovland E; Bangstad HJ; Nygård K; Bjerre A
    BMC Infect Dis; 2016 Jun; 16():285. PubMed ID: 27297224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases.
    Bianchi L; Gaiani F; Vincenzi F; Kayali S; Di Mario F; Leandro G; De' Angelis GL; Ruberto C
    Acta Biomed; 2018 Dec; 89(9-S):153-157. PubMed ID: 30561409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort.
    Monet-Didailler C; Godron-Dubrasquet A; Madden I; Delmas Y; Llanas B; Harambat J
    Pediatr Nephrol; 2019 Apr; 34(4):657-662. PubMed ID: 30368614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemolytic Uremic Syndrome-Induced Acute Kidney Injury Treated via Immunomodulation with the Selective Cytopheretic Device.
    Hambrick HR; Short K; Askenazi D; Krallman K; Pino C; Yessayan L; Westover A; Humes HD; Goldstein SL
    Blood Purif; 2023; 52(9-10):812-820. PubMed ID: 37607519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Post-diarrheal haemolytic uremic syndrome: when shall we consider it? Which follow-up?].
    Bertholet-Thomas A; Ranchin B; King LA; Bacchetta J; Belot A; Gillet Y; Collardeau-Frachon S; Cochat P
    Arch Pediatr; 2011 Jul; 18(7):823-30. PubMed ID: 21571510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shiga toxin-producing Escherichia coli hemolytic uremic syndrome.
    Peco-Antić A
    Srp Arh Celok Lek; 2016; 144(11-12):664-9. PubMed ID: 29659236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome.
    Ylinen E; Salmenlinna S; Halkilahti J; Jahnukainen T; Korhonen L; Virkkala T; Rimhanen-Finne R; Nuutinen M; Kataja J; Arikoski P; Linkosalo L; Bai X; Matussek A; Jalanko H; Saxén H
    Pediatr Nephrol; 2020 Sep; 35(9):1749-1759. PubMed ID: 32323005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children.
    McKee RS; Schnadower D; Tarr PI; Xie J; Finkelstein Y; Desai N; Lane RD; Bergmann KR; Kaplan RL; Hariharan S; Cruz AT; Cohen DM; Dixon A; Ramgopal S; Rominger A; Powell EC; Kilgar J; Michelson KA; Beer D; Bitzan M; Pruitt CM; Yen K; Meckler GD; Plint AC; Bradin S; Abramo TJ; Gouin S; Kam AJ; Schuh A; Balamuth F; Hunley TE; Kanegaye JT; Jones NE; Avva U; Porter R; Fein DM; Louie JP; Freedman SB;
    Clin Infect Dis; 2020 Apr; 70(8):1643-1651. PubMed ID: 31125419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurological involvement in children with hemolytic uremic syndrome.
    Costigan C; Raftery T; Carroll AG; Wildes D; Reynolds C; Cunney R; Dolan N; Drew RJ; Lynch BJ; O'Rourke DJ; Stack M; Sweeney C; Shahwan A; Twomey E; Waldron M; Riordan M; Awan A; Gorman KM
    Eur J Pediatr; 2022 Feb; 181(2):501-512. PubMed ID: 34378062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hemolytic uremic syndrome caused by Shiga-toxin-producing Escherichia coli].
    Loirat C
    Rev Prat; 2013 Jan; 63(1):11-6. PubMed ID: 23457821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.
    Ağbaş A; Göknar N; Akıncı N; Yıldırım ZY; Taşdemir M; Benzer M; Gökçe İ; Candan C; Küçük N; Uzuner S; Özçelik G; Demirkol D; Sever L; Çalışkan S
    Pediatr Nephrol; 2018 Dec; 33(12):2371-2381. PubMed ID: 30159625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prodromal Phase of Hemolytic Uremic Syndrome Related to Shiga Toxin-Producing Escherichia coli: The Wasted Time.
    Balestracci A; Meni Battaglia L; Toledo I; Martin SM; Alvarado C
    Pediatr Emerg Care; 2021 Oct; 37(10):e625-e630. PubMed ID: 31290797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.
    Percheron L; Gramada R; Tellier S; Salomon R; Harambat J; Llanas B; Fila M; Allain-Launay E; Lapeyraque AL; Leroy V; Adra AL; Bérard E; Bourdat-Michel G; Chehade H; Eckart P; Merieau E; Piètrement C; Sellier-Leclerc AL; Frémeaux-Bacchi V; Dimeglio C; Garnier A
    Pediatr Nephrol; 2018 Aug; 33(8):1385-1394. PubMed ID: 29572749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.